Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | C5AR1 | P21730 | 2/20 | 0.63 |
| ▸ | CXCR4 | P61073 | 10/20 | 0.62 |
| ▸ | GLP1R | P43220 | 5/20 | 0.57 |
| ▸ | GCGR | P47871 | 4/20 | 0.57 |
| ▸ | NPY1R | P25929 | 1/20 | 0.56 |
| ▸ | NPY2R | P49146 | 1/20 | 0.56 |
| ▸ | NPY4R | P50391 | 1/20 | 0.56 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.56 |
| ▸ | GIPR | P48546 | 1/20 | 0.56 |
| ▸ | CTSL | P07711 | 1/20 | 0.56 |
| ▸ | CTSH | P09668 | 1/20 | 0.56 |
| ▸ | CTSS | P25774 | 1/20 | 0.56 |
| ▸ | CTSK | P43235 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29913348 | 0.90 | C5AR1 (0.58) | C5AR1CXCR4GLP1RGCGRGIPR | |
| SCHEMBL30881892 | 0.90 | C5AR1 (0.70) | C5AR1CXCR4GLP1RGCGRNPY1R | |
| SCHEMBL29509248 | 0.90 | KEAP1 (0.64) | C5AR1CXCR4GLP1RGCGRNPY1R | |
| SCHEMBL31593265 | 0.89 | RAMP3 (0.54) | CXCR4 | |
| SCHEMBL30859276 | 0.88 | NPY1R (0.65) | C5AR1CXCR4GLP1RGCGRNPY1R | |
| SCHEMBL31146340 | 0.88 | CXCR4 (0.65) | C5AR1CXCR4NPY1RNPY2RNPY4R | |
| SCHEMBL29429574 | 0.88 | GLP1R (0.69) | C5AR1GLP1RGCGRNPY1RNPY2R | |
| SCHEMBL30945042 | 0.88 | CXCR4 (0.66) | C5AR1CXCR4 | |
| SCHEMBL30415232 | 0.88 | C5AR1 (0.67) | C5AR1CXCR4GLP1RGCGRNPY1R | |
| SCHEMBL29655839 | 0.87 | CXCR4 (0.63) | C5AR1CXCR4GLP1RGCGRNPY1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250171776-A1 | NON-CANONICAL CELL-PENETRATING PEPTIDES FOR ANTISENSE OLIGOMER DELIVERY | SAREPTA THERAPEUTICS, INC. (US) | 2025-05-29 | — | — | US | claimed |
| US-20250171776-A1 | NON-CANONICAL CELL-PENETRATING PEPTIDES FOR ANTISENSE OLIGOMER DELIVERY | SAREPTA THERAPEUTICS, INC. (US) | 2025-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250171776-A1 | NON-CANONICAL CELL-PENETRATING PEPTIDES FOR ANTISENSE OLIGOMER DELIVERY | MYOF, TNNC1, MTPN | C5AR1 704/4885CXCR4 2331/4885GLP1R 1414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.